These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 10749562)

  • 1. Antagonists to the rescue.
    Welch WJ; Howard M
    J Clin Invest; 2000 Apr; 105(7):853-4. PubMed ID: 10749562
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
    Morello JP; Salahpour A; Laperrière A; Bernier V; Arthus MF; Lonergan M; Petäjä-Repo U; Angers S; Morin D; Bichet DG; Bouvier M
    J Clin Invest; 2000 Apr; 105(7):887-95. PubMed ID: 10749568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Freedom of expression. Focus on "Endoplasmic reticulum stress and the unfolded protein response regulate cystic fibrosis transmembrane conductance regulator expression".
    Bradbury NA
    Am J Physiol Cell Physiol; 2007 Feb; 292(2):C687-8. PubMed ID: 17005602
    [No Abstract]   [Full Text] [Related]  

  • 5. Aquaretic-induced apoptosis: a cure or a curse?
    Bolignano D; Medici MA; Buemi M
    Eur J Clin Invest; 2008 Nov; 38(11):874-5. PubMed ID: 19021707
    [No Abstract]   [Full Text] [Related]  

  • 6. Modulating the folding of P-glycoprotein and cystic fibrosis transmembrane conductance regulator truncation mutants with pharmacological chaperones.
    Wang Y; Loo TW; Bartlett MC; Clarke DM
    Mol Pharmacol; 2007 Mar; 71(3):751-8. PubMed ID: 17132688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rescuing protein conformation: prospects for pharmacological therapy in cystic fibrosis.
    Gelman MS; Kopito RR
    J Clin Invest; 2002 Dec; 110(11):1591-7. PubMed ID: 12464661
    [No Abstract]   [Full Text] [Related]  

  • 8. Repair of CFTR folding defects with correctors that function as pharmacological chaperones.
    Loo TW; Clarke DM
    Methods Mol Biol; 2011; 741():23-37. PubMed ID: 21594776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cystic fibrosis: premature degradation of mutant proteins as a molecular disease mechanism.
    Gelman MS; Kopito RR
    Methods Mol Biol; 2003; 232():27-37. PubMed ID: 12840537
    [No Abstract]   [Full Text] [Related]  

  • 10. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis.
    Sermet-Gaudelus I; Boeck KD; Casimir GJ; Vermeulen F; Leal T; Mogenet A; Roussel D; Fritsch J; Hanssens L; Hirawat S; Miller NL; Constantine S; Reha A; Ajayi T; Elfring GL; Miller LL
    Am J Respir Crit Care Med; 2010 Nov; 182(10):1262-72. PubMed ID: 20622033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction: molecular chaperones of the ER: their role in protein folding and genetic disease.
    Brooks DA
    Semin Cell Dev Biol; 1999 Oct; 10(5):441-2. PubMed ID: 10597626
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of Kikume green-red fusions to study the influence of pharmacological chaperones on trafficking of G protein-coupled receptors.
    Ridelis I; Schmidt A; Teichmann A; Furkert J; Wiesner B; Schülein R
    FEBS Lett; 2012 Mar; 586(6):784-91. PubMed ID: 22306118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro CFTR folding assays.
    Stidham RD; Wigley WC; Thomas PJ
    Methods Mol Med; 2002; 70():311-22. PubMed ID: 11917534
    [No Abstract]   [Full Text] [Related]  

  • 14. Twenty years after cystic fibrosis gene identification: Where are we and what are we up to?
    Edelman A; Fritsch J; Ollero M
    Pathol Biol (Paris); 2011 Jun; 59(3):131-3. PubMed ID: 19896304
    [No Abstract]   [Full Text] [Related]  

  • 15. SR-121463. Sanofi-Synthélabo.
    Martinez-Castelao A
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1423-7. PubMed ID: 11890358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Specific rescue of cystic fibrosis transmembrane conductance regulator processing mutants using pharmacological chaperones.
    Wang Y; Bartlett MC; Loo TW; Clarke DM
    Mol Pharmacol; 2006 Jul; 70(1):297-302. PubMed ID: 16624886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids.
    Lim M; McKenzie K; Floyd AD; Kwon E; Zeitlin PL
    Am J Respir Cell Mol Biol; 2004 Sep; 31(3):351-7. PubMed ID: 15191910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Base treatment corrects defects due to misfolding of mutant cystic fibrosis transmembrane conductance regulator.
    Namkung W; Kim KH; Lee MG
    Gastroenterology; 2005 Dec; 129(6):1979-90. PubMed ID: 16344066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of novel vasopressin receptor antagonists on renal function and cardiac hypertrophy in rats with experimental congestive heart failure.
    Bishara B; Shiekh H; Karram T; Rubinstein I; Azzam ZS; Abu-Saleh N; Nitecki S; Winaver J; Hoffman A; Abassi ZA
    J Pharmacol Exp Ther; 2008 Aug; 326(2):414-22. PubMed ID: 18467593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
    J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.